OBI Pharma : Announcement on behalf of AP Biosciences that preemptive rights forfeited by directors are over 50% and made available to specific persons
Announcement on behalf of AP Biosciences that
preemptive rights forfeited by directors are over 50%
and made available to specific persons
Date of events
2022/08/08
To which item it meets
paragraph 45
Statement
1.Date of occurrence of the event:2022/08/08
2.Reason for the forfeiture of subscription rights by the
directors nd supervisors:
In accordance with related laws and regulations, to coordinate with AP
Biosciences' future plan of shareholding dispersal after IPO, and to
protect shareholders' interests of the Company, OBI decides to forfeit all
the preemptive rights of AP Biosciences' cash capital increase and
distribute the rights to shareholders of OBI.
3.Name of director/supervisor, number of shares forfeited,
and the percentage out of total subscription:
Director:OBI Pharma Inc.
7,864,657 shares forfeited, percentage out of total subscription:100%
4.Name(s) of the specific person(s) and no.of shares subscribed:
Total amount available for shareholders of OBI is 7,864,657 shares. Based
on the shareholding ratio stated on the register of shareholders on the
book closure date, each thousand shares of OBI bears the preemptive rights
for 34.3016 shares of AP Biosciences.
5.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
OBI Pharma Inc. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 08:53:08 UTC.
OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.
OBI Pharma : Announcement on behalf of AP Biosciences that preemptive rights forfeited by directors are over 50% and made available to specific persons